



17<sup>th</sup> December 2012

Company's Announcement Office  
ASX Limited  
Exchange Centre  
20 Bridge Street  
Sydney NSW 2000

## **ASX ANNOUNCEMENT / MEDIA RELEASE**

### **Notice of Allowance received from USPTO on “Use of Metal Complexes” patent**

- **Patent covers the use of Mix&Go™ to facilitate binding processes**
- **Further strengthens Anteo's IP protection & commercial position**
- **Vital step toward positive Freedom to Operate assessment by any US licensees**

Anteo Diagnostics Limited (ASX: ADO) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the “Use of Metal Complexes” patent for Mix&Go™.

“Use of Metal Complexes” is the key patent for Mix&Go™ technology, and, given that this patent has already been granted in Japan and accepted in Australia, this Notice of Allowance in the US represents another encouraging development for Anteo.

Under normal circumstances the USPTO would be expected to grant the “Use of Metal Complexes” patent within three months of issuance of the Notice of Allowance once all of the requisite fees have been paid.

The number of US patents granted to Australian biotechnology companies remains relatively small so this development is a major achievement for the company and provides further validation of our ground breaking Mix&Go™ technology. It is another critical step in strengthening the company's commercial position and protecting Anteo's intellectual property (IP) in this large and important market.

As previously mentioned, there are many commercially important reasons to bind biological molecules such as proteins onto synthetic materials like plastics or polystyrene. These molecules are often fragile and do not react well when exposed to non-biological conditions. The “Use of Metal Complexes” patent covers the IP for the use of Mix&Go™ to facilitate this important binding process.

This US Patent has significant ramifications for Anteo's dealings with potential customers for licensing and other commercial agreements. Larger companies wanting to license Mix&Go™ for

***Anteo Diagnostics Limited*** ABN 75 070 028 625

**Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113**

**Phone 07 3219 0085 Fax 07 3219 0553 Email [contact@anteodx.com](mailto:contact@anteodx.com) Web [www.anteodx.com](http://www.anteodx.com)**



incorporation into their own products will undertake their own “Freedom to Operate” analysis before entering into any agreement and launching any products that contain Mix&Go™. A granted patent streamlines this process and reduces ambiguity.

Anteo’s Chief Executive Officer Dr. Geoff Cumming commented: “Anteo is very pleased to receive Notification of Allowance for such an important and valuable patent in the commercially significant US market. We believe that its granting will be viewed favourably by the many groups with whom we are collaborating in the US.”

“We continue to focus on advancing negotiations for new licensing agreements. Protecting the IP surrounding the Mix&Go™ technology is critical for future commercial success.”

ENDS

**For More Information Contact  
Dr Geoff Cumming, CEO  
Anteo Diagnostics Limited  
Tel: +61 7 3219 0085**

***Anteo Diagnostics Limited*** ABN 75 070 028 625  
Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

**Phone** 07 3219 0085 **Fax** 07 3219 0553 **Email** [contact@anteodx.com](mailto:contact@anteodx.com) **Web** [www.anteodx.com](http://www.anteodx.com)

For personal use only